Molecular diagnosis and prognosis in gynecologic oncology

Archives of Pathology and Laboratory Medicine

Volumn 123, Issue 11, 1999, Pages 1035-1040

  Silverberg, Steven C ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FEMALE; GENE THERAPY; GENETIC ANALYSIS; GYNECOLOGIC CANCER; HUMAN; MICROSATELLITE INSTABILITY; PROGNOSIS; TREATMENT PLANNING; TUMOR BIOPSY; UTERINE CERVIX CANCER;

ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TECHNIQUES; GENITAL NEOPLASMS, FEMALE; HUMANS; OVARIAN NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0032743674     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Katsube Y, Berg JW Silverberg SG. Epidemiologicpathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol. 1982;1:3-16.
2. Ozols RF, Rubin SC, Dembo AJ, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Ferez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia, Pa: Lippincott; 1992:731-782.
3. Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS, Paterson JM. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol. 1999;30:151-157.
4. Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, Cerny T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol. 1998;70:176-182.
5. Eltabbakh GH, Piver MS, Hempling RE, et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol. 1998;70:392-397.
6. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol. 1993;12:120-127.
7. Siriaunkgul S, Robbins KM, McGowan L, Silverberg SG. Ovarian mucinous tumors of low malignant potential: a clincopatholgic study of 54 tumors of intestinal and mullerian type. Int J Gynecol Pathol. 1995;14:198-208.
8. Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy: the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer. 1993;3:349-358.
9. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319-1330.
10. Katabuchi H, Tashiro H, Cho KR, Kurman RJ, Ellenson LH. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol. 1998;17:54-60.
11. Zaloudek C. Sex cord-stromal tumors of the ovary. Pathol Case Rev. 1997;2:187-193.
12. Mok SC, Tsao SW, Knapp RC, et al. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res. 1992;52:5119-5122.
13. Tsao SW, Mok SC, Knapp RC, et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol. 1993;48:5-10.